About Geron Corporation
https://www.geron.comGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
CEO
Harout Semerjian
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-07-22 | Forward | 529:500 |
ETFs Holding This Stock
Summary
Showing Top 3 of 125
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Needham
Buy
Stifel
Buy
B. Riley Securities
Buy
Barclays
Overweight
Scotiabank
Sector Perform
HC Wainwright & Co.
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:60.38M
Value:$81.51M
BLACKROCK, INC.
Shares:46.61M
Value:$62.92M
BLACKROCK INC.
Shares:46.55M
Value:$62.85M
Summary
Showing Top 3 of 332
About Geron Corporation
https://www.geron.comGeron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $47.23M ▼ | $39M ▼ | $-18.43M ▼ | -39.02% ▼ | $-0.03 ▼ | $-9.66M ▼ |
| Q2-2025 | $49.04M ▲ | $60.3M ▲ | $-16.38M ▲ | -33.39% ▲ | $-0.02 ▲ | $-7.55M ▲ |
| Q1-2025 | $39.6M ▼ | $55.1M ▼ | $-19.84M ▲ | -50.08% ▲ | $-0.03 ▲ | $-11.33M ▲ |
| Q4-2024 | $47.54M ▲ | $66.8M ▲ | $-25.35M ▲ | -53.33% ▲ | $-0.04 ▲ | $-16.33M ▲ |
| Q3-2024 | $28.27M | $56.03M | $-26.45M | -93.55% | $-0.04 | $-23.2M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $380.53M ▼ | $567.38M ▲ | $318.68M ▲ | $248.71M ▼ |
| Q2-2025 | $387.98M ▼ | $555.2M ▼ | $295.67M ▲ | $259.53M ▼ |
| Q1-2025 | $396.88M ▼ | $562.45M ▼ | $294.21M ▼ | $268.24M ▼ |
| Q4-2024 | $406.57M ▲ | $593.78M ▲ | $313.46M ▲ | $280.32M ▼ |
| Q3-2024 | $339.77M | $444.95M | $152.67M | $292.28M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-18.43M ▼ | $-13.58M ▲ | $13.35M ▼ | $542K ▼ | $389K ▲ | $-13.49M ▲ |
| Q2-2025 | $-16.38M ▲ | $-27.41M ▲ | $20.32M ▼ | $1.09M ▲ | $-6.01M ▼ | $-27.55M ▲ |
| Q1-2025 | $-19.84M ▲ | $-47.98M ▼ | $52.44M ▲ | $256K ▼ | $4.73M ▼ | $-47.98M ▼ |
| Q4-2024 | $-25.35M ▲ | $-43.95M ▲ | $-103.51M ▼ | $166.16M ▲ | $18.68M ▲ | $-43.8M ▲ |
| Q3-2024 | $-26.45M | $-58.94M | $-554K | $3.58M | $-55.87M | $-58.94M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Government Rebates | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product | $50.00M ▲ | $40.00M ▼ | $50.00M ▲ | $50.00M ▲ |
 Revenues Before Adjustments | $60.00M ▲ | $50.00M ▼ | $60.00M ▲ | $60.00M ▲ |
 Sales Returns And Allowance | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Total Gross To Net Adjustments | $0 ▲ | $-10.00M ▼ | $-10.00M ▲ | $-10.00M ▲ |
 Chargeback And Distributor Service Fees | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Harout Semerjian
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-07-22 | Forward | 529:500 |
ETFs Holding This Stock
Summary
Showing Top 3 of 125
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Needham
Buy
Stifel
Buy
B. Riley Securities
Buy
Barclays
Overweight
Scotiabank
Sector Perform
HC Wainwright & Co.
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:60.38M
Value:$81.51M
BLACKROCK, INC.
Shares:46.61M
Value:$62.92M
BLACKROCK INC.
Shares:46.55M
Value:$62.85M
Summary
Showing Top 3 of 332